The Role of SOCS2 and IGF-I in Breast Cancer Prognosis
Author Information
Author(s): Haffner Michael C, Petridou Barbara, Peyrat Jean Phillipe, Révillion Françoise, Müller-Holzner Elisabeth, Daxenbichler Günter, Marth Christian, Doppler Wolfgang
Primary Institution: Innsbruck Medical University
Hypothesis
The study aims to elucidate the clinicopathological features associated with SOCS1, SOCS2, SOCS3, CIS, and IGF-I expression in breast cancer.
Conclusion
High expression of SOCS2 and IGF-I is associated with better prognosis in breast cancer patients, particularly in those with lymph-node negative disease.
Supporting Evidence
- Patients with high SOCS2 expression lived significantly longer (108.7 vs. 77.7 months; P = 0.015).
- High SOCS2 expression proved to be an independent predictor for good prognosis (HR = 0.45, 95% CI 0.23 – 0.91, P = 0.026).
- High IGF-I expression was a strong predictor for favorable outcome in lymph-node negative patients (HR = 0.075, 95% CI 0.014 – 0.388, P = 0.002).
Takeaway
This study found that higher levels of two proteins, SOCS2 and IGF-I, in breast cancer patients can mean they live longer and have a better chance of recovery.
Methodology
mRNA expression levels of SOCS1, SOCS2, SOCS3, CIS, and IGF-I were determined in 89 primary breast cancers using reverse transcriptase PCR.
Participant Demographics
{"median_age":62.2,"age_range":"35 to 81","gender":"female"}
Statistical Information
P-Value
0.015
Confidence Interval
0.23 – 0.91
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website